Leniolisib not checked

Pharming Technologies B.V.

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 3 trial completes
Trials
3 active
8 in total · 6 in the EU
Targets
 

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.Kinase Inhibitor FDA class
How it’s given
“The doses selected range from 20 to 70 mg BID (resulting in total daily doses ranging from 40 to 140 mg per day) based on weight. The doses will be administered as (a combination of) 10 mg and 30 mg tablets”In the company’s words, NCT05438407 on ClinicalTrials.gov
Tested for
APDS (2 trials), PIDs Linked to PI3K
Main trialPhase 3
“This is a 2-part, prospective, open-label, single arm, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of leniolisib in at least 15 pediatric patients (aged 4 to 11 years) with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).”In the company’s words, NCT05438407 on ClinicalTrials.gov
Other names
Joenja

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 30 Nov 2026 Pediatric Patients Aged 4 to 11 Years With APDS
Phase 3Active, not recruiting 9 Jul 2028 Pediatric Patients Aged 1 to 6 Years With APDS
Phase 2Active, not recruiting 12 Aug 2029 Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation
Phase 3Unknown 31 Jan 2025 An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS
Phase 2Completed 23 Jun 2026 Leniolisib for Immune Dysregulation in PIDs
Phase 2Completed 12 Aug 2026 Leniolisib for Immune Dysregulation in CVID
Phase 1Ended not given An open-label cocktail drug-drug interaction (DDI) clinical study to assess the effect of multiple oral dosing with leniolisib on the pharmacokinetics (PK) of caffeine, midazolam, rosuvastatin, furosemide, and metformin in healthy subjects
Phase 1Ended not given A six-way relative bioavailability study comparing 10, 30, 40 and 50 mg leniolisib film coated tablets and 30 mg film coated granules with 70 mg film coated tablet in healthy volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Leniolisib

Following is part of Solo: you see every change to Leniolisib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in